Does TIGIT benefit no one…
Or does it benefit a biologically defined subset we failed to identify? 🤔
All-comers trials and conventional biomarkers ignore heterogeneous tumour immune contexts.
Is it time for true precision IO? 🔬
#ImmunoOncology #PrecisionMedicine #Biomarkers
TIGIT’s immuno-oncology teachings
www.nature.com/articles/d41...
Drug developers spent billions of dollars on clinical trials of TIGIT-blocking cancer immunotherapies, but have little to show for it. What went wrong?
